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Objective: To assess and characterize antibiotic resistance in Acinetobacter baumannii
strains recovered from 5 health-care facilities in Algiers.
Methods: Antibiotic susceptibility testing was performed by agar diffusion and agar
dilution methods, resistance genes were identiﬁed by PCR and sequencing, and molecular
typing of isolates was carried out by enterobacterial repetitive intergenic consensus-PCR
(ERIC-PCR).
Results: Among 125 tested isolates, 117 (93.6%) were multidrug-resistant, of which 94
(75.2%) were imipenem resistant. The blaADC and blaOXA-51-like genes were detected in
all isolates, in association with ISAba1 sequence in 84% and 8% (imipenem resistant) of
isolates, respectively. The blaOXA-23-like and blaOXA-24-like carbapenemase genes were
detected in 67.02% and 20.21% of imipenem-resistant isolates, respectively. The blaOXA-
23-like gene is linked to ISAba1 or ISAba4 elements. The metallo-b-lactamase NDM-1
gene was found in 10 (10.6%) imipenem-resistant strains from three hospitals, it is
linked to ISAba125 element in nine strains. Extended spectrum b-lactamases production
was not detected. Imipenem and cefotaxime resistance phenotypes could not be trans-
ferred to Escherichia coli by conjugation. Outer membrane protein CarO gene was not
detected in four imipenem-resistant isolates. The aac(60)-Ib, sul1, sul2, tetA and tetB
genes were present in 5.31%, 36.17%, 77.65%, 1.06% and 65.92% of strains, respec-
tively. Class 1 integrons were detected in 23.4% strains. ERIC-PCR typing showed a
genetic diversity among blaOXA-23-like and blaOXA-24-like positive strains, while clonality
was observed among blaNDM-1 positives.
Conclusions: This study highlighted the high prevalence of imipenem resistance in
Acinetobacter baumannii in Algiers hospitals mediated mainly by blaOXA-23-like, blaOXA-
24-like, and blaNDM-1 genes.1. Introduction
Acinetobacter baumannii (A. baumannii) is a gram-negative
cocobacilli characterized by its ubiquity and its ability to
persist in hospital environment and easily acquire antibioticresistance. It is an opportunistic pathogen responsible for
nosocomial infections mainly by cross-transmission, with a
propensity for outbreak. A. baumannii is naturally resistant to
penicillin G, amoxicillin and ﬁrst and second cephalosporin
generations by producing a cephalosporinase of ADC type
(Acinetobacter-Derived Cephalosporinases) and secondarily
through an oxacillinase represented by blaOXA-51-like cluster [1,2].
Overexpression of ADCs through upstream inserting of insertion
sequences [2,3] and/or production of extended-spectrum beta-
lactamases (ESBLs) are mechanisms of acquired resistance to
broad spectrum cephalosporins [1,4]. The resistance to
carbapenems is most often related to the acquisition ofopen access article under the CC BY-NC-ND
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D b-lactamases (CHDLs) distributed into the following main
clusters: intrinsic OXA-51-like and acquired OXA-23-like,
OXA-24-like/40, OXA-58-like and OXA-143-like; (ii) metallo-
b-lactamases (MBLs) of IMP, VIM, SIM, GIM and NDM types;
(iii) carbapenemases of Ambler class A as KPC and some var-
iants of GES [1,4,5]. Insertion sequences present at the 50 end and/
or 30 end of blaOXA genes regulate their expression and mobility,
particularly by the formation of transposon structures [5]. MBLs
of IMP, VIM and SIM types are often described as gene
cassettes of class 1 integrons which are the most prevalent in
A. baumannii [4], and NDM was found associated with an
upstream ISAba125 element and can be located within a
transposon named Tn125 [6]. Moreover, non-enzymatic mecha-
nisms were described such as modiﬁcation of membrane
permeability through loss of outer membrane proteins, such as
CarO [2,7]. Despite worldwide reports on the increase of
morbidity and mortality associated with A. baumannii, to our
best knowledge, few studies were devoted to this germ in
Algeria, particularly in Algiers region which has the highest
concentration of population and hospitals. More data are
needed in order to objectively appreciate the state and
epidemiology of antibiotic resistance. The objective of this
study was to assess and characterize the antibiotic resistance in
clinical A. baumannii isolates recovered from 5 health-care fa-
cilities in Algiers.
2. Materials and methods
2.1. Bacterial isolates
The study included 125 non repetitive strains of
A. baumannii collected from ﬁve health care institutions in
Algiers, Zemirli hospital (n = 91), Beni-Messous hospital
(n = 12), Burn Central Clinic (n = 9), Birtraria hospital (n = 7)
and Anti-cancer Center Pierre and Marie Curie of Mustapha
hospital (n = 6). The strains were isolated during the period
2008–2014 from various clinical specimens: bronchial ﬂuid
(n = 43), pus (n = 37), blood (n = 11), urine (n = 10), catheters
(n = 6), cerebrospinal ﬂuid (n = 3), bile (n = 1) and unspeciﬁed
(n = 14). These specimens were from various care units: inten-
sive care (n = 54), neurosurgery (n = 20), orthopedic (n = 10),
burn (n = 9), hematology (n = 4), general surgery (n = 2),
marrow transplantation (n = 2), internal medicine (n = 1),
emergency (n = 1), rehabilitation (n = 1), outpatients (3) and
unspeciﬁed (n = 18). The strains were identiﬁed by standard
microbiological techniques, API 20NE identiﬁcation systems
(BioMerieux, France) and by PCR detection of the intrinsic
carbapenemase gene blaOXA-51-like [8].
2.2. Antibiotic susceptibility testing
Antibiotic susceptibility was determined by the disk diffusion
method on Mueller–Hinton agar, according to the recommen-
dations of the Antibiogram Committee of the French Society for
Microbiology [9]. The following antibiotic disks (Bio-Rad) were
used (mg or International Unit ‘‘IU’’/disk): amoxicillin/clavulanic acid (20/10 mg), ticarcillin (TIC) (75 mg),
piperacillin (PIP) (75 mg), piperacillin/tazobactam (PTZ) (75/
10 mg), cefotaxime (CTX) (30 mg), ceftazidime (CAZ)
(30 mg), ceftriaxone (CRO) (30 mg), cefepime (CFP) (30 mg),
aztreonam (AZT) (30 mg), imipenem (IMP) (10 mg),
ciproﬂoxacin (CIP) (5 mg), oﬂoxacine (OFL) (5 mg),
peﬂoxacin (PEF) (5 mg), gentamicin (GM) (15 mg), amikacin
(AMK) (30 mg), tetracyclines (TE) (30 mg), trimethoprim/
sulfamethoxazole (SXT) (1.25/23.75 mg) and colistin (C)
(50 mg). Escherichia coli (E. coli) ATCC 25922 was used as a
control.
The MICs of cefotaxime (CTX), ceftazidime (CAZ), imipe-
nem (IMP), ciproﬂoxacin (CIP), gentamicin (GM) and trimeth-
oprim/sulfamethoxazole (SXT) were determined by agar-
dilution method according to the guidelines of CA-SFM [9].
2.3. Phenotypic detection of production of metallo-b-
lactamases (MBLs) and extended-spectrum-b-
lactamases (ESBLs)
MBLs production was screened by the imipenem-EDTA
double-disk synergy (IEDDS) test using disks of imipenem
(10 mg) and EDTA (1.5 mg) spaced at a distance of 15 mm (edge
to edge) on Mueller–Hinton agar [10].
ESBLs production was screened by the Double-Disc Synergy
Test (DDST) [11] using disks of cefotaxime, ceftazidime and
cefepime placed around a disk of amoxicillin/clavulanic acid
at a distance of 20 mm from disk center to center on Mueller–
Hinton agar supplemented with cloxacillin (500 mg/mL).
2.4. Detection of antibiotic resistance genes, insertion
sequences and integrons
Simplex and multiplex PCR were used to screen for the
following resistance genes as previously described: OXA car-
bapenemases: blaOXA-51-like, blaOXA-23-like, blaOXA-24-like,
blaOXA-58-like [12] and blaOXA-143 [13]; metallo-b-lactamases:
blaIMP, blaVIM, blaGIM and blaNDM-1 [14,15]; cephalosporinase:
blaADC [16]; class A beta-lactamases: blaTEM, blaSHV [17],
blaCTX-M [18], blaPER, blaVEB, blaGES [19]; plasmid-mediated
quinolone resistance determinants: qnrA, qnrB and qnrS [20];
aminoglycoside-modifying enzyme: aac(60)-Ib [20]; tetracycline
efﬂux pumps: tetA and tetB [21]; dihydropteroate synthases:
sul1, sul2 and sul3 [22,23]; dihydrofolate reductases: dfrA1,
dfrA5, dfrA7, dfrA8 and dfrA12 [24].
Insertion sequences ISAba1, ISAba4 and ISAba125 were
searched by PCR as previously described [3,25,26]. The genetic
association between ISAba1, ISAba4 and ISAba125 sequences
and blaADC, blaOXA-51-like, blaOXA-23-like, blaOXA-24-like and
blaNDM-1 genes was investigated by PCR using combinations
of forward or reverse primers of ISAba sequences and bla genes.
Screening for class 1 and class 2 integrons was done by
multiplex PCR targeting int1, sul1 and qacDE genes and by
simplex PCR targeting int2 gene [22,27]. carO gene was searched
by PCR as previously described [7]. All primers used were
presented in Table 1.
Table 1
Primers used in this study.
Target Primer Sequence 50/30 AT (C) ES (bp) Ref
blaOXA-23-like OXA-23-F GATCGGATTGGAGAACCAGA 52 501 [12]
OXA-23-R ATTTCTGACCGCATTTCCAT
blaOXA-24-like OXA-24-F GGTTAGTTGGCCCCCTTAAA 52 246 [12]
OXA-24-R AGTTGAGCGAAAAGGGGATT
blaOXA-58-like OXA-58-F AAGTATTGGGGCTTGTGCTG 52 599 [12]
OXA-58-R CCCCTCTGCGCTCTACATAC
blaOXA-51-like OXA-51-F TAATGCTTTGATCGGCCTTG 52 353 [12]
OXA-51-R TGGATTGCACTTCATCTTGG
blaOXA-143-like OXA-143-F TGGCACTTTCAGCAGTTCCT 52 149 [13]
OXA-143-R TAATCTTGAGGGGGCCAACC
blaVIM VIMgen-F2 GTTTGGTCGCATATCGCAAC 53 382 [14]
VIMgen-R2 AATGCGCAGCACCAGGATAG
blaIMP IMPgen-F1 GAATAGAATGGTTAACTCTC 53 188 [14]
IMPgen-R1 CCAAACCACTAGGTTATC
blaGIM GIM-F1 TCAATTAGCTCTTGGGCTGAC 53 72 [14]
GIM-R1 CGGAACGACCATTTGAATGG
blaNDM-1 NDM-Fm GGTTTGGCGATCTGGTTTTC 52 621 [15]
NDM-Rm CGGAATGGCTCATCACGATC
ISAba-1 ISAba1a ATGCAGCGCTTCTTTGCAGG 55 393 [3]
ISAba1b AATGATTGGTGACAATGAAG
ISAba-4 ISAba4A ATTTGAACCCATCTATTGGC 40 611 [25]
ISAba4B ACTCTCATATTTTTTCTTGG
ISAba-125 125F GGGTAATGCTCGTATCGT 48 148 [26]
125R TAGACGTAGACGTGGTCA
blaTEM TEM up ATGATGATTCAACATTTCCG 52 858 [17]
TEM low CCAATGCTTAATCAGTGAGG
blaSHV SHV up TTATCTCCCTGTTAGCCACC 50 795 [17]
SHV low GATTTGCTGATTTCGCTCGG
blaCTX-M CTX-MA CGCTTTGCGATGTGCAG 55 550 [18]
CTX-MB ACCGCGATATCGTTGGT
blaPER PER-1F ATGAATGTCATTATAAAAGC 55 925 [19]
PER-1B AATTTGGGCTTAGGGCAGAA
blaVEB VEB-1F CGACTTCCATTTCCCGATGC 55 643 [19]
VEB-1B GGACTCTGCAACAAATACGC
blaGES GES-1F ATGCGCTTCATTCACGCAC 55 860 [19]
GES-1B CTATTTGTCCGTGCTCAGG
blaADC ADC1 CCGCGACAGCAGGTGGATA 51 420 [16]
ADC2 TCGGCTGATTTTCTTGGTT
qnr A qnrAm F AGAGGATTTCTCACGCCAGG 54 580 [20]
qnrAm R TGCCAGGCACAGATCTTGAC
qnr B qnrBm F GGMATHGAAATTCGCCACTG 54 246 [20]
qnrBm R TTTGCYGYYCGCCAGTCGAA
qnr S qnrSm F GCAAGTTCATTGAACAGGGT 54 428 [20]
qnrSm R TCTAAACCGTCGAGTTCGGCG
aac(60)Ib aac(6)-F TTGCGATGCTCTATGAGTGGCTA 55 482 [20]
aac(6)-R CTCGAATGCCTGGCGTGTTT
tet A TetA-F GTAATTCTGAGCACTGTCGC 62 954 [21]
TetA-R CTGCCTGGACAACATTGCTT
tet B TetB-F CTCAGTATTCCAAGCCTTTG 57 414 [21]
TetB-R ACTCCCCTGAGCTTGAGGGG
intI 1 intI 1-F CCTTCGAATGCTGTAACCGC * 248 [22]
intI 1-R ACGCCCTTGAGCGGAAGTATC
qacED1 qacED1-F GAGGGCTTTACTAAGCTTGC * 200 [22]
qacED1-R ATACCTACAAAGCCCCACGC
sul1 Sul1-F TCAGACGTCGTGGATGTCG * 346 [22]
Sul1-R CGAAGAACCGCACAATCTCG
sul2 Sul2 up GCGCTCAAGGCAGATGGCATT 69 293 [23]
Sul2 low GCGTTTGATACCGGCACCCGT
sul 3 Sul3 up GGAAGAAATCAAAAGACTCAA 53 363 [23]
Sul3 low CCTAAAAAGAAGCCCATACC
intI 2 IntI2-F GTAGCAAACGAGTGACGAAATG 60 789 [27]
IntI2-R CACGGATATGCGACAAAAAGGT
dfr A1 dfr A1-F GTGAAACTATCACTAATGG 46 471 [24]
dfr A1-R ACCCTTTTGCCAGATTTG
dfr A5 dfr A5-F GCBAAAGGDGARCAGCT 52 394 [24]
dfr A5-R TTTMCCAYATTTGATAGC
dfr A7 dfr A7-F AAAATTTCATTGATTTCTGCA 52 471 [24]
dfr A7-R TTAGCCTTTTTTCCAAATCT
dfr A8 dfr A8-F TTGGGAAGGACAACGCACTT 46 382 [24]
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Table 1 (continued )
Target Primer Sequence 50/30 AT (C) ES (bp) Ref
dfr A8-R ACCATTTCGGCCAGATCAAC
dfr A12 dfr A12-F GGTGAGCARAAGATYTTTCGC 46 309 [24]
dfr A12-R TGGGAAGAAGGCGTCACCCTC
carO CarO-F AAAGTATTACGTGTTTTAGTG 55 750 [7]
CarO-R TTACCAGTAGAAGTTTACACC
ERIC2 ERIC2 AAGTAAGTGACTGGGGTGACGC 30 / [28]
AT: Annealing temp; ES: Expected size; *: 65 C, decrease by 1 C by cycle for 10 cycles and 55 C for 24 cycles.
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24-like, blaOXA-23-like, blaNDM-1, ISAba125/blaNDM-1 and aac(60)-
Ib were sequenced and analyzed with the BLAST and FASTA
programs of the National Center for Biotechnology Information
(www.ncbi.nlm.nhi.gov).
2.5. Molecular genotyping of isolates
The clonal relationship between imipenem-resistant isolates
was investigated by enterobacterial repetitive intergenic
consensus-PCR (ERIC-PCR) using primer ERIC2 [28] at
annealing temperature of 30 C. Fingerprints were visually
compared and strains showing dissimilarity by one band or
more were considered as different [29].
2.6. Conjugation experiments
Mating experiments were performed using sodium azide
resistant E. coli BM21 as a recipient. Exponential cultures of
A. baumannii isolates as donor (1 vol) and recipient (2 vol) wereTable 2
Antimicrobial resistance rates of A. baumannii isolates from Algiers hospita
Antibiotic (disc load) Breakpointa
(zone in mm)
Phenotypes
imipenem-resista
(n = 94) (
S <R R I
Ticarcillin (75 mg) 22 18 100.00 0.00
Piperacillin (75 mg) 22 18 100.00 0.00
Piperacillin/Tazobactam
(75/10 mg)
19 14 96.80 3.19
Amoxicilline/Clavulanate
(20/10 mg)
23 16 94.68 5.31
Cefotaxime (30 mg) 26 23 100.00 0.00
Ceftriaxone(30 mg) 26 23 100.00 0.00
Ceftazidime (30 mg) 21 19 91.48 2.12
Cefepime (30 mg) 21 19 88.29 9.57
Aztreonam (30 mg) 23 21 95.74 3.19
Imipenem (10 mg) 24 17 92.55 7.44
Peﬂoxacin (5 mg) 22 16 84.04 7.44
Oﬂoxacin (5 mg) 22 22 90.42 0.00
Ciproﬂoxacin (5 mg) 22 22 90.42 0.00
Gentamicin (15 mg) 16 16 80.85 0.00
Amikacin (30 mg) 17 15 67.02 10.63
Tetracycline (30 mg) 19 17 78.72 7.44
Trimethoprim/Sulfamethoxazole
(1,25/23,75 mg)
16 13 94.68 3.19
Colistin (50 mg) 15 15 0.00 0.00
a Breakpoints and susceptibility were interpreted according to CA-SFM (2
b S: susceptible; I: intermediate; R: resistant.inoculated as a spot on Brain Heart Infusion Agar (BHIA). After
overnight incubation at 37 C, transconjugants were selected on
BHIA supplemented with cefotaxime (4 mg/mL) or imipenem
(2 mg/mL) and sodium azide (300 mg/mL).
3. Results
Of the 125 A. baumannii strains, 87 showed resistance to
imipenem and 7 intermediate resistance. All these 94 imipenem-
resistant strains were also resistant to ticarcillin, piperacillin,
piperacillin/tazobactam, amoxicillin/clavulanic acid, cefotaxime
and ceftriaxone, and 93.60%, 97.86% and 98.93% were resistant
to ceftazidime, cefepime and aztreonam, respectively. For non-
beta-lactams, resistance rates were 90.42%, 90.42% and
91.48% for ciproﬂoxacin, oﬂoxacin and peﬂoxacin, 77.65% and
80.85% for amikacin and gentamicin, and 86.16% and 97.87%
for tetracycline and trimethoprim/sulfamethoxazole. All strains
were susceptible to colistin (Table 2). Agar dilution MICs of
imipenem, cefotaxime, ceftazidime, ciproﬂoxacin, gentamicin
and trimethoprim/sulfamethoxazole were, respectively, from 8ls (n = 125).
b of
nt isolates
%)
Phenotypesb of
imipenem-susceptible
isolates (n = 31) (%)
Phenotypesb of
total isolates
(n = 125) (%)
S R I S R I S
0.00 64.51 6.45 29.03 91.20 1.60 7.20
0.00 61.29 12.09 25.80 90.40 3.20 6.40
0.00 3.22 35.48 61.29 73.60 11.20 15.20
0.00 35.48 45.16 29.03 80.00 15.20 4.80
0.00 83.87 6.45 9.67 96.00 1.60 2.40
0.00 87.09 3.22 9.67 96.00 1.60 2.40
6.38 61.29 9.67 29.03 84.80 3.20 12.00
2.12 29.04 12.09 58.06 72.80 10.40 16.80
1.06 77.41 6.45 16.12 91.20 3.20 5.60
0.00 0.00 0.00 100.00 69.60 5.60 24.80
8.51 41.94 19.35 38.70 72.80 10.40 16.80
9.57 64.51 0.00 35.45 85.60 0.00 14.40
9.57 54.83 0.00 45.16 82.40 0.00 17.60
19.14 67.74 0.00 32.25 76.80 0.00 23.20
22.34 51.61 6.45 41.93 63.20 9.60 27.20
13.82 58.06 3.22 38.70 72.80 5.60 21.60
2.12 67.74 9.67 32.27 88.00 2.40 9.60
100.00 0.00 0.00 100.00 0.00 0.00 100.00
013).
Table 3
Antimicrobial resistance patterns and b-lactamase genes of imipenem-resistant A. baumannii isolates (n = 94).
Hospital Care
units
Specimens Dates Cephalosporinase and
carbapenemase genes
IMP
MICs
mg/mL
Antibiotic resistance patterns (resistant + intermediate) (n) No. of
isolates
ZM Orthopedic,
intensive care
bronchial ﬂuid,
pus
2010–2013 blaADC, blaoxa-51-like 16–32 TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-AN-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-AN-SXT-TE (1)
2
ZM
BM
Intensive care
neurosurgery
orthopedic outpatient
bronchial ﬂuid,
catheter, blood,
pus, urine
2013–2014 blaADC, blaoxa-51-like,
blaoxa-24-like
8–128 TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-AN-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-IMP-PEF-CIP-OFX-GM-AN-SXT-TE (2)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-SXT-TE (2)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-AN-SXT-TE (14)
19
ZM
BM
BCC
BR
PMCC
Neurosurgery, hematology
intensive care, orthopedic,
burn, general surgery
rehabilitation, emergency
not speciﬁed
bronchial ﬂuid,
pus, blood,
cerebrospinal ﬂuid,
not speciﬁed
2009–2014 blaADC, blaoxa-51-like,
blaoxa-23-like
8–128 TIC-PIP-PPT-AMC-CTX-CRO-IMP-AN-SXT (1)
TIC-PIP-PPT-AMC-CTX-CRO-ATM-IMP-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-IMP-GM-AN-SXT (1)
TIC-PIP-PPT-AMC-CTX-CRO-ATM-FEP-IMP-GM-AN-SXT-TE (2)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-GM-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-GM-AN-SXT (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-GM-AN-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-ATM-FEP-IMP-OFX-GM-AN-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-ATM-FEP-IMP-PEF-CIP-OFX-AN-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-SXT-TE (5)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-SXT (2)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-AN-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-AN-SXT-TE (6)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-SXT-TE (5)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-AN-SXT-TE (34)
63
ZM
BM
PMCC
Neurosurgery, orthopedic
intensive care,
marrow-transplantation,
internal medicine
bronchial ﬂuid,
cerebrospinal ﬂuid,
catheter, pus, bile
2012–2014 blaADC, blaoxa-51-like,
blaNDM-1
32–128 TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-SXT (8)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-SXT-TE (1)
TIC-PIP-PPT-AMC-CTX-CRO-CAZ-ATM-FEP-IMP-PEF-CIP-OFX-GM-AN-SXT-TE (1)
10
TIC: ticarcillin; PIP: piperacillin; PPT: piperacillin/tazobactam; AMC: amoxicillin/clavulanate; CTX: cefotaxime; CRO: ceftriaxone; CAZ: ceftazidime; ATM: aztreonam; FEP: cefepime; IMP: imipenem; PEF:
peﬂoxacin; CIP: ciproﬂoxacin; OFX: oﬂoxacin; GM: gentamicin; AN: amikacin, SXT: trimethoprim/sulfamethoxazole; TE: tetracycline. ZM: Zemirli hospital; BCC: Burn central clinic; BM: Beni-Messous hospital;
BR: Birtraria hospital; PMCC: Pierre and Marie Curie Centre; MIC: Minimal inhibitory concentration.
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Figure 2. ERIC-PCR ﬁngerprints of NDM-1 positive imipenem-resistant
A. baumannii isolates (n = 10).
S27, S46, S58, S59, S64: isolates from Zemirli hospital; S100: isolate from
Beni-Messous hospital; S114, S115, S116, S117: isolates from Pierre and
Marie Curie Centre; M1 and M2: 1 kb and 100 bp DNA markers ladder
(Promega).
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128 mg/mL, 1 to >64 mg/mL and 2/38 to >32/608 mg/mL.
The prevalence of antibiotic resistance was relatively lower
for some antibiotics in the 31 imipenem-susceptible strains,
namely ticarcillin (70.96%), piperacillin (73.38%), piperacillin/
tazobactam (38.70%), ceftazidime (70.96%), cefepime
(41.13%), ciproﬂoxacin (54.83%), oﬂoxacin (64.51%), peﬂox-
acin (61.29%), gentamicin (67.74%) and tetracycline (61.26%)
(Table 2).
Sixteen resistance proﬁles including 9–17 antibiotics were
deﬁned among imipenem-resistant strains, and 24 proﬁles
including 3–16 antibiotics among imipenem-susceptible strains.
All imipenem-resistant strains and almost all imipenem-
susceptible strains (74.2%) were multidrug-resistant (MDR),
they were resistant to at least three classes of antibiotics
(Table 3).
The ADC type cephalosporinase gene was detected in all
isolates and its association with ISAba1 in 105 isolates, 87 of the
94 imipenem-resistant and 18 of the 31 imipenem-susceptible.
The screening for ADC/ISAba125 association in the 20
remaining strains was negative.
Phenotypic detection of ESBL and PCR screening for b-
lactamases SHV, CTX-M, PER, VEB and GES genes were
negative, while TEM gene was detected in 32 strains.
The screening for OXA-type carbapenemases revealed the
presence the blaOXA-51-like gene in all isolates. ISAba1 was
found upstream of blaOXA-51-like gene in only 10 (8%)
imipenem-resistant strains, while it was detected in 116 (92.8%)
strains, 93 of 94 imipenem-resistant strains and 23 of 31
imipenem-susceptible strains. blaOXA-23-like gene was detected
by PCR and sequencing in 63 imipenem-resistant strains from
the 5 hospitals. The presence of ISAba1 and ISAba4 upstream of
blaOXA-23-like gene in opposite orientation was showed in 37 and
18 imipenem-resistant strains, respectively. The 8 remaining
blaOXA-23-like positive strains did not show association with these
insertion sequences. blaOXA-24-like gene was found in 19
imipenem-resistant strains from Zemirli and Beni Messous
hospitals, without association with any insertion sequences.
Genes encoding OXA-58-like and OXA-143-like carbapene-
mases were not detected (Table 3).
Phenotypic test for metallo-b-lactamases production was
positive for 10 imipenem-resistant strains (Figure 1), all
harbored the NDM-1 gene detected by PCR and sequencing.
These strains from various clinical specimens were from Zemirli
hospital (5 isolates), Pierre and Marie Curie Center (4 isolates)
and Beni Messous hospital (1 isolate) (Table 3). The insertion
sequence ISAba125 was detected in the 10 strains, and found
upstream of blaNDM-1 gene in the same orientation in 9 strains.
The NDM-1 strain without association with ISAba125 was fromFigure 1. Detection of metallo-b-lactamase production by the imipenem-
EDTA synergy test.Beni Messous hospital. Metallo-b-lactamases IMP, VIM and
GIM were not detected.
Conjugation experiments performed on imipenem-resistant
strains have not allowed transfer of cefotaxime or imipenem
resistance to the recipient strain E. coli BM21.
The gene of the outer membrane protein CarO was not
detected in four imipenem-resistant strains harboring OXA-51-
like (n = 1), OXA-51-like + OXA-23-like (n = 1) and OXA-
51-like + ISAba1/OXA-23-like (n = 2).
The two remaining imipenem-resistant strains without OXA
or NDM-1 carbapenemases had an ISAba1/OXA-51-like asso-
ciation or a loss of the outer membrane protein CarO gene.
The screening for resistance genes to other classes of anti-
biotics in the 94 imipenem-resistant strains showed the absence
of PMQR [qnr and aac(60)-Ib-cr], dfr and sul3 genes, while
aac(60)-Ib, sul1, sul2, tetA and tetB were detected in 5 (5.31%),
34 (36.17%), 73 (77.65%), 1 (1.06%) and 62 (65.92%) strains,
respectively. Class 1 integrons were detected in 22 (23.4%)
strains, while class 2 integrons were absent.
Molecular typing of the 94 imipenem-resistant strains per-
formed by ERIC-PCR identiﬁed 57 DNA proﬁles. The 63 OXA-
23 strains presented 41 different genetic proﬁles and the 19
OXA-24 strains showed 10 different DNA proﬁles. The 10
NDM-1 strains showed 4 DNA proﬁles, the same genetic proﬁle
for the 4 strains from Pierre and Marie Curie Center, two for the
5 strains from Zemirli hospital, and a speciﬁc proﬁle for the
single strain from Beni-Messous hospital (Figure 2).
4. Discussion
The widespread of carbapenem-resistant A. baumannii con-
stitutes a global public health threat. Molecular characterization
of mechanisms and epidemiology of multidrug-resistance is a
main step to tackle its spreading and develop therapeutic stra-
tegies. Seventy ﬁve percent of A. baumannii strains collected
from 5 hospitals in Algiers were resistant to imipenem. This rate
is higher than that previously reported in Algeria in a national
survey (45.32%) [30], but similar to that more recently reported
in Western Algeria (70.8%) [31]. Overall, carbapenem
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imipenem-resistant strains has reached 100% in some coun-
tries [32]. This evolution may be due to a heavy use of
carbapenems, notably following the pandemic of ESBLs,
particularly CTX-M type, and also to the no compliance with
hygiene and isolation procedures in some countries.
All our imipenem-resistant strains were multidrug resistant,
as commonly reported worldwide [33,34], this is maybe inherent
to the accumulation of mutations selected by various antibiotics
before introduction of carbapenems, and to the multiple
mechanisms of carbapenem resistance in A. baumannii
conferring simultaneous resistance to antibiotics of other classes.
Resistance patterns of our strains leave very few therapeutical
options. In this study, like in previous reports from Algeria
[31,35], all our isolates were susceptible to colistin. Overall, MDR
Acinetobacter strains remain susceptible to colistin, fosfomycine
and tigecycline. In vitro and animal studies support the role of
combination therapy of colistin with fosfomycine or
tigecycline and with other molecules as rifampicine and
vancomycine or teicoplamine [4,6,36]. Besides imipenem, it
also should be noted the very high prevalence of aztreonam
resistance in our strains. This antibiotic, which normally is not
or weakly hydrolyzed by OXA- and MBL-carbapenemases
types (including NDM-1), constitutes a therapeutic solution in
combination with a large broad spectrum serine beta-lactamases
inhibitor [6].
The ADC gene was present in all strains in agreement with
the ubiquitous nature of this gene responsible for A. baumannii
natural resistance to penicillins and 3rd generation cephalospo-
rins [16,26]. Resistance to cephalosporins may also be due to the
acquisition of ESBL; no synergy between clavulanic acid and
antibiotic markers was observed in our strains. The search for
beta-lactamases previously identiﬁed in A. baumannii, namely
TEM, SHV, CTX-M, PER, VEB and GES, was positive for only
TEM. In agreement with our results, no ESBLs were detected in
imipenem-resistant A. baumannii in Western Algeria [31] and the
narrow spectrum beta-lactamases TEM-1 and TEM-2 were
described as prevalent in Acinetobacter [1,4].
The screening for OXA-type enzymes with potent carbape-
nemase activity showed the presence of OXA-51-like in all
strains, these enzymes are known as ubiquitous and intrinsic to
A. baumannii species [8,27].
OXA-23-like and OXA-24-like were detected in 67.02% and
20.21% of imipenem resistant strains, respectively, with a total
of 87.23%. OXA-23-like is the most prevalent of carbapena-
mases with a global distribution and OXA-23-producing
A. baumannii strains were described as cause of nosocomial
outbreaks [5,27,37]. OXA-24-like is also a widely disseminated
cluster, however at a lesser prevalence than OXA-23-like [5]. In
Algeria, Oxa-23-like and OXA-24-like were previously reported
in Eastern and Western Algeria [31,35,38] and just recently in a
hospital in Algiers [39].
Because of their low expression, blaADC and blaOXA genes
have weak hydrolytic activity on oxymino-beta-lactams and
carbapenems, their expression level becomes clinically signiﬁ-
cant by the presence of upstream insertion sequences providing
them with strong promoters. blaADC gene present in all strains
was found linked to ISAba1 in 84% of strains, this association is
commonly reported in A. baumannii, resulting in high resistance
to broad spectrum cephalosporins, particularly ceftazidime
[3,16,26], as was observed in our strains. blaOXA-51-like were found
associated with ISAba1 in only 10 strains, while this IS wasdetected in 116 (92.8%) strains and it was described as the
most frequently associated with blaOXA-51-like [40]. However,
other IS such as ISAba825 can provide effective promoters to
blaOXA-51-like gene, contributing to carbapenem resistance [41].
Almost all detected blaOXA-23-like genes (87.3%) were found
associated with ISAba1 or ISAba4, in agreement with previous
studies showing the role of these sequences in overexpression
of blaOXA-23-like in A. baumannii [25,27,40]. blaOXA-24-like genes
were not found associated with any insertion sequence in our
strains, as was already reported [4,42]. In addition to their role
as “mobile promoter”, insertion sequences are involved in
mobilization of resistance genes conferring them a high
potential of diffusion.
Ten strains (10.63%) harbored the MBL gene blaNDM-1, they
were recovered from different clinical specimens in three hos-
pitals, Zemirli, Pierre and Marie Curie Center and Beni Mes-
sous. NDM-1 was previously reported by other authors in
Western Algeria [31] and just recently in Eastern Algeria and in a
hospital in Algiers [39]. This MBL detected originally in
enterobacteria was later described in Acinetobacter, with a link
with the Indian subcontinent and in some cases with the
Balkan region and the Middle East [6]. However, this enzyme
has rapidly spread throughout the world reaching at last
Central and South America [43,44]. NDM-1 strains were recov-
ered from national patients who do not seem to have had any
recent contact with abroad. The same observation was reported
about NDM-1 strains in Western Algeria [31]. This would
suggest that NDM-1 is possibly endemic in Algeria. Nine of
the 10 NDM-1 strains have been found associated with
ISAba125, as already described [45]. This sequence can
positively affect the expression of NDM-1 and contribute to
its mobilization through a composite transposon consisting of
two ISAba125 (Tn125) [45].
Conjugation assays have not allowed transfer of cefotaxime
and imipenem resistance to E. coli; this may be related to
chromosomal location of carbapenemase genes, instability of
Acinetobacter-derived plasmids in E. coli or non self trans-
ferability of plasmids.
CarO outer membrane protein was described as contributing
in the inﬂux of carbapenems in A. baumannii and a reduced
susceptibility to carbapenems can result from insertional inac-
tivation of CarO [7]. In our study, the non detection of carO gene
in four strains suggests its deletion, the same observation was
already reported [46].
Concerning non-beta-lactam resistance genes, plasmid-borne
quinolone resistance genes [qnr and aac(60)-Ib-cr] were not
detected in this study, in agreement with the rarity of PMQR
determinants in A. baumannii [47,48]. The most frequently
resistance mechanisms to ﬂuoroquinolones are mutations in
topoisomerases genes and efﬂux pumps such as AdeABC [2].
aac(60)-Ib gene was found in ﬁve gentamicin- and amikacin-
resistant strains from Beni-Messous hospital, it is commonly
reported in A. baumannii [1]. In agreement in our study, the
prevalence of trimethoprim/sulfamethoxazole resistance in
A. baumannii is high in many geographic regions [4].
Although acquired-dfr genes were previously reported within
integron structures [4,49], none of dfr gene clusters was
detected in our strains. Trimethoprim resistance in
Acinetobacter can be related to housekeeping dfr genes and to
efﬂux systems [50,51]. Sulfonamides resistance genes sul1 and
sul2 genes were highly present in our strains, they are
commonly described in Acinetobacter and are predictive of the
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among our tetracycline-resistant strains (76.54%) compared to
tetA, as previously reported in Acinetobacter [53], tetB also
confers resistance to minocycline [2]. The tetracycline
resistance of tet-negative strains is probably due to other efﬂux
pumps [53]. Integrons provide an additional means of mobility
and expression to resistance genes, class 1 integrons were
identiﬁed in 23.4% of imipenem-resistant isolates which were
sul1 positive. Class 1 integrons are very common in multidrug
resistant A. baumannii [27,54] and most acquired MBL genes
were located within these genetic elements [4,55].
ERIC-PCR analysis revealed globally a genetic diversity
among OXA-23-like and OXA-24-like positive strains, multiple
clones have coexisted in hospitals and care units indicating a
polyclonal dissemination, which may be due to multiple reser-
voirs as fecal carriers and environmental sources, and to the
diffusion of mobile genetic elements. Except the single strain
from Beni Messous hospital, a clonal relatedness was observed
for strains harboring NDM-1 gene from Pierre and Marie Curie
Center and Zemirli hospital. This ﬁnding suggests clonal
emergence of NDM-1-producing strains, maybe promoted by
cross-transmission.
In conclusion, this study reported the high prevalence of
multidrug resistant A. baumannii in Algiers hospitals, with
imipenem resistance mediated by ISAba1- and ISAba4-associ-
ated blaOXA-23-like, blaOXA-24-like and ISAba125-associated
blaNDM-1. A genetic diversity was observed for OXA-23-like-
and OXA-24-like-producing strains, while clonality has char-
acterized the NDM-1 strains. These ﬁndings report a critical
situation that requires compliance with the rules of hygiene,
patient isolation, identiﬁcation of germ sources, implementation
of treatment strategies, and careful monitoring of antibiotic
resistance evolution.
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